WEP Clinical (WEP), a clinical services company that works with pharmaceutical companies to help patients and physicians gain access to medicines when treatment options are limited or unavailable, has partnered with Plusultra pharma (PUP) to distribute HYFTOR® 2 mg/g gel to patients living in EU/EEA countries, with the exception of Germany.
HYFTOR® (Sirolimus) is indicated for the treatment of facial angiofibroma associated with tuberous sclerosis complex (facial AF-TSC) in adult and paediatric patients aged 6 years and older. EMA marketing authorisation was granted on 15th May 2023 and the Orphan Drug Designation was maintained at the time of the authorisation.
Reference: European public assessment reports (EPAR)
The WEP HYFTOR® distribution program has been designed to ensure that physicians in the EU/EEA (in countries other than Germany) can access HYFTOR® for the treatment of their patients suffering from facial AF-TSC.
Jas Khera, Managing Director of WEP, said:
“We are excited to partner with Plusultra pharma to provide access to HYFTOR® in EU/EEA countries other than Germany. This programme will help ensure that patients with facial AF-TSC will have a much-needed treatment option available to them, and we are proud to be a part of such an effort.”
For physicians who are interested in further information on the HYFTOR® programme and how to access the product, please contact WEP at: email@example.com.
About WEP Clinical
At WEP Clinical, we are With Every Patient, as we believe every patient should have access to treatment! With this as our guiding principle, we have created a market leading, solutions driven, healthcare services company that partners with drug developers to create broader treatment access solutions for patients worldwide. We take pride in the high-quality output and positive customer experience we create while delivering our services. We specialize in the following: Expanded Access and Post-Approval Named Patient Programs; Market Access Solutions; Home Nursing Services for Decentralized Clinical Trials; and Clinical Trial Sourcing. For more information, please visit www.wepclinical.com.
About Plusultra Pharma (PUP)
Plusultra pharma GmbH (PUP) was established in 2020 with headquarters based in Düsseldorf, Germany, as a 100% affiliated company of Nobelpharma Co Ltd Tokyo Japan. Nobelpharma and PUP have a strong pipeline thattargets rare diseases and thus intend to commercialisese drugs with high unmet needs.
PUP also has a legal entity as a business operations unit in the UK (Oxford), responsible for the distribution, sales, and marketing activities in the UK territory.
PUP is engaged in the management of clinical research and commercial operations on behalf of Nobelpharma Corporation in the EU/EEA, with a proven commercial, regulatory, and medical infrastructure in place.
For more information, please visit https://plusultra-pharma.de/